Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Blueprint Medicines (BPMC)
NASDAQ:BPMC
Blueprint Medicines (BPMC) Stock Price & Analysis
496 Followers
BPMC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$43.89 - $101.00
Previous Close$88.38
Volume79.61K
Average Volume (3M)774.04K
Market Cap
$5.52B
Enterprise Value$5.48B
Total Cash (Recent Filing)$710.64M
Total Debt (Recent Filing)$774.12M
Price to Earnings (P/E)-10.6
Beta1.42
Next Earnings
May 01, 2024EPS Estimate
-$1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.37
Shares Outstanding61,232,297
10 Day Avg. Volume543,639
30 Day Avg. Volume774,041
Standard Deviation0.14
R-Squared0.06
Alpha0.00495
Financial Highlights & Ratios
Price to Book (P/B)40.36
Price to Sales (P/S)75.21
Price to Cash Flow (P/CF)-16.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.63
Enterprise Value/Gross Profit22.73
Enterprise Value/Ebitda-11.59
Forecast
1Y Price Target
$96.90Price Target Upside7.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
Blueprint Medicines News
PremiumCompany Announcements
Blueprint Medicines Divests GAVRETO Rights to Rigel
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentAyvakit showcases long-term efficacy in treating indolent systemic mastocytosis, with positive study results indicating potential improvements in patient care.
Financial PerformanceBlueprint Medicines has a strong cash position and a growing market opportunity in systemic mastocytosis, providing a solid financial foundation for the company.
Product PipelineBLU-222, a CDK2 inhibitor, shows promising antitumor activity in endometrial cancer models, potentially enhancing treatment options and patient outcomes.
Bears Say
Drug PerformanceBezuclastinib exhibited reductions in clinical effectiveness measures that were less effective compared to Ayvakit.
Sales PerformanceGavreto US sales have been disappointing, with annual revenues falling below $30 million.
Strategic DecisionsThe company will discontinue global development and marketing of Gavreto in geographies outside the US and China.
---
Ownership Overview
17.25% Insiders
46.12% Mutual Funds
16.73% Other Institutional Investors
19.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BPMC FAQ
What was Blueprint Medicines’s price range in the past 12 months?
Blueprint Medicines lowest stock price was $43.89 and its highest was $101.00 in the past 12 months.
What is Blueprint Medicines’s market cap?
Currently, no data Available
When is Blueprint Medicines’s upcoming earnings report date?
Blueprint Medicines’s upcoming earnings report date is May 01, 2024 which is in 12 days.
How were Blueprint Medicines’s earnings last quarter?
Blueprint Medicines released its earnings results on Feb 15, 2024. The company reported -$1.82 earnings per share for the quarter, beating the consensus estimate of -$2.04 by $0.22.
Is Blueprint Medicines overvalued?
According to Wall Street analysts Blueprint Medicines’s price is currently Undervalued.
Does Blueprint Medicines pay dividends?
Blueprint Medicines does not currently pay dividends.
What is Blueprint Medicines’s EPS estimate?
Blueprint Medicines’s EPS estimate is -$1.67.
How many shares outstanding does Blueprint Medicines have?
Blueprint Medicines has 61,232,296 shares outstanding.
What happened to Blueprint Medicines’s price movement after its last earnings report?
Blueprint Medicines reported an EPS of -$1.82 in its last earnings report, beating expectations of -$2.04. Following the earnings report the stock price went up 14.023%.
Which hedge fund is a major shareholder of Blueprint Medicines?
Among the largest hedge funds holding Blueprint Medicines’s share is Woodline Partners LP. It holds Blueprint Medicines’s shares valued at 75M.
---
Blueprint Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$96.90 (7.57% Upside)
$96.90 (7.57% Upside)
Blogger Sentiment
Bullish
BPMC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 144.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.09%
12-Months-Change
Fundamentals
Return on Equity
-157.13%
Trailing 12-Months
Asset Growth
-22.27%
Trailing 12-Months
Company Description
Blueprint Medicines
Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
---
BPMC Company Deck
---
BPMC Earnings Call
Q4 2024
0:00 / 0:00
---
BPMC Stock 12 Months Forecast
Average Price Target
$96.90
▲(7.57% Upside)
Technical Analysis
Best Analysts Covering BPMC
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+13.01%
reiterated a buy rating 4 months ago
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +13.01% per trade.
---